Loading
companiesCompany
Cartesian Therapeutics
Cartesian makes CAR-T cells from messenger RNA rather than permanent gene insertion, so the cells work for days and then fade; it began in myeloma and now leads phase 3 trials in autoimmune disease.
Also called: Cartesian Therapeutics, Inc.Cartesian
Overview
Cartesian Therapeutics, based in Frederick, Maryland, engineers T cells with mRNA-encoded chimeric antigen receptors, giving a transient product that can be dosed repeatedly without lymphodepletion. Its BCMA-directed Descartes-08 was first tested in multiple myeloma before the company focused on myasthenia gravis and other autoimmune diseases, where it leads phase 3 trials. Its myeloma trials remain on ClinicalTrials.gov under Cartesian as lead sponsor.
Similar pages
- CompanyJW Pharmaceutical
Shares Pivotal (registrational) trial, Clinical trial, Multiple myeloma.
- CompanyPregLem
- CompanyAngiocrine Bioscience
Shares Pivotal (registrational) trial, Clinical trial, Multiple myeloma.
- CompanyAgennix
- CompanyLisata Therapeutics
- CompanyImmunitor
- CompanyEmergent BioSolutions
- PersonNoopur Raje
Shares BCMA, CAR-T cell therapy, Multiple myeloma.